Lithium is a metal salt prescribed as a mood stabilizer, most often for bipolar disorder. It is not a controlled substance under federal law, and it is not one of the drug classes that a standard workplace urine or oral fluid panel is built to detect. Employees who take lithium sometimes ask whether a pre employment or random screening will flag it, or whether the blood draws their psychiatrist orders are connected to workplace testing at all. The short answer is that the two are separate systems measuring completely different things, and understanding why helps explain what a drug test panel actually targets.
What a standard drug test panel is designed to find
Workplace drug testing programs, including the federal model that many private employers follow, are built around immunoassay screening for specific drug classes such as amphetamines, cocaine metabolites, marijuana metabolites, opioids, and phencyclidine. The Substance Abuse and Mental Health Services Administration (SAMHSA) publishes the authorized testing panels and cutoff levels for federal workplace programs, and the current panel composition is detailed in the Federal Register notice on Mandatory Guidelines for Federal Workplace Drug Testing Programs, Authorized Testing Panels. Lithium is a light metal ion, not an amphetamine, opioid, cannabinoid, or any other compound those immunoassay strips are manufactured to bind to. There is no documented cross reactivity between lithium and the antibodies used in standard rapid test cups, dip cards, or oral fluid devices, because the test chemistry is simply not built to react with it.
SAMHSA also maintains general guidance and resources on drug free workplace programs, including specimen collection procedures and panel information, at its drug testing resources page. Employers building or reviewing a testing policy should rely on that kind of primary source rather than assumptions about what a panel covers, since panels vary by program type and by employer choice within the drugs of abuse categories.
What lithium monitoring actually measures
Patients prescribed lithium undergo a completely different kind of blood test, generally called a serum lithium level. This is a clinical laboratory test ordered by a prescriber, not a workplace screening tool, and it measures the concentration of lithium ion circulating in the blood to keep the dose inside a narrow therapeutic window. The FDA prescribing information requirements for lithium carbonate products, searchable through the agency's drug product database and reflected in the product specific guidance documents such as the one published by the FDA on lithium carbonate, describe why this monitoring matters: the concentration associated with therapeutic benefit sits close to the concentration associated with toxicity, so clinicians check blood levels periodically rather than relying on symptoms alone.
The official prescribing label, available through the National Library of Medicine's DailyMed listing for lithium carbonate, instructs prescribers to confirm serum lithium concentrations before and during therapy and warns that toxicity can occur at doses close to therapeutic levels. That is a clinical safety measure built around dosing, not a screening for misuse, and it has no functional overlap with a workplace drug panel.
The pharmacology and toxicity profile of lithium are summarized in two NIH Bookshelf resources written for clinicians: a general overview of the drug's mechanism and use in the StatPearls entry on lithium, and a dedicated review of overdose presentation and management in the StatPearls entry on lithium toxicity. Both describe the narrow range between an effective dose and a toxic one, which is the reason for routine serum monitoring and the reason that monitoring looks nothing like a workplace drug screen.
Comparing workplace drug screening with lithium level monitoring
| Feature | Workplace drug test panel | Serum lithium monitoring |
|---|---|---|
| Purpose | Detect recent use of specific controlled substances or drug classes | Confirm the prescribed dose is in a safe, effective range |
| Who orders it | Employer, under a workplace policy | Prescribing clinician, as part of ongoing care |
| Specimen type | Urine, oral fluid, or other matrix specified by policy | Venous blood |
| Method | Immunoassay screening, with lab confirmation for non negative results | Quantitative serum assay reported as a numeric concentration |
| Does it target lithium | No, lithium is not one of the drug classes on standard panels | Yes, that is the entire purpose of the test |
| Result interpreted by | Laboratory and, for non negative results, a Medical Review Officer | Prescribing clinician against a therapeutic range |
What happens if a prescription comes up in the review process
Because lithium is not a panel analyte, it will not itself trigger a non negative screening result. The more common scenario where prescription medications intersect with workplace testing involves other drug classes on the panel, such as prescribed stimulants or opioids, where a laboratory confirmed non negative result is routed to a Medical Review Officer (MRO) for review. The MRO is a licensed physician trained to interpret confirmed laboratory results in light of legitimate medical explanations. If an employee has a valid prescription relevant to a flagged result, that documentation is verified through the MRO process rather than through the collection site or the employer directly. Keeping current prescription records and being reachable for an MRO interview, if a sample is ever sent for confirmation on an unrelated analyte, is the practical step that protects an employee regardless of what medication they take.
Employers should not assume that any psychiatric medication, including lithium, will or will not appear in a report, and should rely on their laboratory and MRO for analyte specific questions rather than guessing. Program design and cutoff levels can vary between employers and between federal and non federal programs, so a specific panel's scope should always be confirmed against the laboratory's published analyte list rather than assumed from general information like this article.
Frequently asked questions
Does a standard 5 panel or 10 panel drug test detect lithium?
No. Standard panels target drug classes such as amphetamines, cocaine, marijuana, opioids, and phencyclidine. Lithium is not chemically related to any of those classes and is not included as an analyte on standard immunoassay panels.
Is lithium a controlled substance?
No. Lithium carbonate is a prescription medication regulated through the standard FDA drug approval and labeling process, but it is not scheduled under the federal Controlled Substances Act the way opioids or stimulants are.
Why do people on lithium need regular blood tests if it is not tested for at work?
Serum lithium monitoring is a clinical safety measure, separate from workplace testing. It confirms the dose keeps blood concentration inside the narrow range where the medication works without reaching toxic levels, as described in the drug's prescribing information.
Could lithium cause a false positive on a workplace drug screen?
There is no documented cross reactivity between lithium and the antibody based immunoassays used in standard workplace drug test panels. If a non negative result occurs for an unrelated analyte, it is reviewed by a Medical Review Officer, who considers any prescription medication as part of that review.
Should an employee tell their employer they take lithium?
That is a personal medical privacy decision. Employees generally are not required to disclose medications unless a non negative laboratory result requires an MRO interview, at which point relevant prescriptions are discussed confidentially with the MRO rather than with the employer.
Where can I find the official list of drugs on a federal workplace testing panel?
The authorized panel and cutoff levels for federal workplace drug testing programs are published by SAMHSA and in the Federal Register, which are the primary sources employers and testing providers should reference directly rather than relying on summaries.
Building a panel that matches your program's needs
Employers designing or reviewing a testing program should work from the analyte list their laboratory publishes, not from assumptions about what any single medication will or will not trigger. American Screening Corporation supplies a range of drug test cups configured to the standard drug classes employers actually need to screen for, with lab confirmation available for any non negative screening result. For background on how other prescribed medications interact with standard panels, see our related posts on medications that can cause a false positive on drug tests and why tricyclic antidepressants appear on some screening panels.
This article is general information only and is not legal or medical advice. Employers should consult qualified counsel on testing policy and employees should consult their prescribing clinician regarding any medication question.
